David Urso, MEI Pharma CEO
September 29, 2023 09:36 AM EDT
Pharma

MEI Phar­ma push­es back on ac­tivist in­vestors af­ter failed merg­er with In­fin­i­ty

Kyle LaHucik

Senior Reporter

MEI Phar­ma is in de­fense mode af­ter ac­tivist in­vestors called for the re­moval of the San Diego biotech’s en­tire board and a cash re­turn to …

Endpoints News

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER
TRENDING NOW

WuXi AppTec will sell cell and gene ther­a­py busi­ness to pri­vate eq­ui­ty firm

The End­points 2024 win­ners and losers list: Who was up and who was down in bio­phar­ma

Ca­griSe­ma’s weight loss da­ta dis­ap­point­ed. What does No­vo do next?

CMS ex­plains what went in­to its first round of drug price ne­go­ti­a­tions

Ex­clu­sive: Flori­da can­cer biotech rais­es $100M Se­ries A

No­vo Nordisk’s once-dai­ly he­mo­phil­ia drug Al­he­mo ap­proved in US

A service from the Financial Times